Literature DB >> 1309587

The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells.

S C Kenney1, E Holley-Guthrie, E B Quinlivan, D Gutsch, Q Zhang, T Bender, J F Giot, A Sergeant.   

Abstract

Regulation of replicative functions in the Epstein-Barr virus (EBV) genome is mediated through activation of a virally encoded transcription factor, Z (BZLF1). We have shown that the Z gene product, which binds to AP-1 sites as a homodimer and has sequence similarity to c-Fos, can efficiently activate the EBV early promoter, BMRF1, in certain cell types (i.e., HeLa cells) but not others (i.e., Jurkat cells). Here we demonstrate that the c-myb proto-oncogene product, which is itself a DNA-binding protein and transcriptional transactivator, can interact synergistically with Z in activating the BMRF1 promoter in Jurkat cells (a T-cell line) or Raji cells (an EBV-positive B-cell), whereas the c-myb gene product by itself has little effect. The simian virus 40 early promoter is also synergistically activated by the Z/c-myb combination. Synergistic transactivation of the BMRF1 promoter by the Z/c-myb combination appears to involve direct binding by the Z protein but not the c-myb protein. A 30-bp sequence in the BMRF1 promoter which contains a Z binding site (a consensus AP-1 site) is sufficient to transfer high-level lymphoid-specific responsiveness to the Z/c-myb combination to a heterologous promoter. That the c-myb oncogene product can interact synergistically with an EBV-encoded member of the leucine zipper protein family suggests c-myb is likely to engage in similar interactions with cellularly encoded transcription factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309587      PMCID: PMC364077          DOI: 10.1128/mcb.12.1.136-146.1992

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  58 in total

1.  Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes.

Authors:  C D Gregory; C Kirchgens; C F Edwards; L S Young; M Rowe; A Forster; T H Rabbitts; A B Rickinson
Journal:  Eur J Immunol       Date:  1987-08       Impact factor: 5.532

2.  Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

Authors:  C Rooney; N Taylor; J Countryman; H Jenson; J Kolman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

3.  Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells.

Authors:  F Toneguzzo; A C Hayday; A Keating
Journal:  Mol Cell Biol       Date:  1986-02       Impact factor: 4.272

4.  Regulation of c-myb expression in human neuroblastoma cells during retinoic acid-induced differentiation.

Authors:  C J Thiele; P S Cohen; M A Israel
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

5.  Structural and functional domains of the myb oncogene: requirements for nuclear transport, myeloid transformation, and colony formation.

Authors:  C E Ibanez; J S Lipsick
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

6.  c-myb protein expression is a late event during T-lymphocyte activation.

Authors:  J S Lipsick; W J Boyle
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

7.  Characterization of enhancer elements in the long terminal repeat of Moloney murine sarcoma virus.

Authors:  L A Laimins; P Gruss; R Pozzatti; G Khoury
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

8.  Differential expression of the c-myb proto-oncogene marks the pre-B cell/B cell junction in murine B lymphoid tumors.

Authors:  T P Bender; W M Kuehl
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

9.  Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.

Authors:  A Chevallier-Greco; E Manet; P Chavrier; C Mosnier; J Daillie; A Sergeant
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

10.  The highly conserved amino-terminal region of the protein encoded by the v-myb oncogene functions as a DNA-binding domain.

Authors:  K H Klempnauer; A E Sippel
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

View more
  30 in total

1.  Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta.

Authors:  J Lu; S Y Chen; H H Chua; Y S Liu; Y T Huang; Y Chang; J Y Chen; T S Sheen; C H Tsai
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation.

Authors:  L K Chang; S T Liu
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

3.  Multivalent sequence recognition by Epstein-Barr virus Zta requires cysteine 171 and an extension of the canonical B-ZIP domain.

Authors:  Pu Wang; Latasha Day; Paul M Lieberman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  The Epstein-Barr virus BMRF1 gene is essential for lytic virus replication.

Authors:  Bernhard Neuhierl; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F.

Authors:  C Liu; N D Sista; J S Pagano
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

6.  Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication.

Authors:  Q Zhang; Y Hong; D Dorsky; E Holley-Guthrie; S Zalani; N A Elshiekh; A Kiehl; T Le; S Kenney
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases.

Authors:  A L Adamson; D Darr; E Holley-Guthrie; R A Johnson; A Mauser; J Swenson; S Kenney
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

8.  Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.

Authors:  A L Adamson; S Kenney
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

9.  Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras.

Authors:  J L Kolman; N Taylor; L Gradoville; J Countryman; G Miller
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

10.  RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism.

Authors:  F B Furnari; V Zacny; E B Quinlivan; S Kenney; J S Pagano
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.